StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) operating KPIs

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)

Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%

Abbott Laboratories u.S. FDA Premarket Approvals (PMA Original & Supplements) — Abbott

U.S. FDA openFDA PMA Database

QuarterlyAnnualMonthly
Latest, Q3 2026
65
Period ended Sep 30, 2026
Change on a year earlier
-5.8%
69 in Q3 2025
History
51 quarters
Since Q1 2014
Sources
1
U.S. FDA openFDA Device Clearances, Approvals, Recalls & MAUDE MDR

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedU.S. FDA Premarket Approvals (PMA Original & Supplements) — AbbottYear on yearSource
Q3 2026Sep 30, 202665-5.8%U.S. FDA openFDA Device Clearances, Approvals, Recalls & MAUDE MDR ↗
Q2 2026Jun 30, 202675-13.8%U.S. FDA openFDA Device Clearances, Approvals, Recalls & MAUDE MDR ↗
Q1 2026Mar 31, 202670+32.1%U.S. FDA openFDA Device Clearances, Approvals, Recalls & MAUDE MDR ↗
Q4 2025Dec 31, 202550-48.5%U.S. FDA openFDA Device Clearances, Approvals, Recalls & MAUDE MDR ↗
Q3 2025Sep 30, 202569-2.8%U.S. FDA openFDA Device Clearances, Approvals, Recalls & MAUDE MDR ↗
Q2 2025Jun 30, 202587+31.8%U.S. FDA openFDA Device Clearances, Approvals, Recalls & MAUDE MDR ↗
Q1 2025Mar 31, 202553-1.9%U.S. FDA openFDA Device Clearances, Approvals, Recalls & MAUDE MDR ↗
Q4 2024Dec 31, 202497+5.4%U.S. FDA openFDA Device Clearances, Approvals, Recalls & MAUDE MDR ↗
Q3 2024Sep 30, 202471+20.3%U.S. FDA openFDA Device Clearances, Approvals, Recalls & MAUDE MDR ↗
Q2 2024Jun 30, 202466+10.0%U.S. FDA openFDA Device Clearances, Approvals, Recalls & MAUDE MDR ↗
Q1 2024Mar 31, 202454+12.5%U.S. FDA openFDA Device Clearances, Approvals, Recalls & MAUDE MDR ↗
Q4 2023Dec 31, 202392+119.0%U.S. FDA openFDA Device Clearances, Approvals, Recalls & MAUDE MDR ↗
Q3 2023Sep 30, 202359+40.5%U.S. FDA openFDA Device Clearances, Approvals, Recalls & MAUDE MDR ↗
Q2 2023Jun 30, 202360+76.5%U.S. FDA openFDA Device Clearances, Approvals, Recalls & MAUDE MDR ↗
Q1 2023Mar 31, 202348+17.1%U.S. FDA openFDA Device Clearances, Approvals, Recalls & MAUDE MDR ↗
Q4 2022Dec 31, 202242-27.6%U.S. FDA openFDA Device Clearances, Approvals, Recalls & MAUDE MDR ↗

Cite this data

StockData. (2026). Abbott Laboratories U.S. FDA Premarket Approvals (PMA Original & Supplements) — Abbott, quarterly Q1 2014–Q3 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/ext-fda-pma-co

See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.